|
Frank Leonard
President, CNS Cancers U.S.
Novocure
|
Frank Leonard has served as President, CNS (central nervous system) Cancers U.S. since September 2022. He is responsible for the entirety of Novocure’s U.S. CNS business, including U.S. glioblastoma (GBM) Sales and Marketing, Regional Marketing, Learning & Development, Maxpoint, Government Affairs and U.S. CNS Medical teams.
Mr. Leonard joined Novocure in 2010 to help prepare the company for the commercial launch of Optune®. He most recently served as Chief Development Officer. In this role, he was responsible for engineering, product development, business development and the overall strategic and operational leadership of Novocure’s innovation platforms. He previously served as the Senior Vice President for Corporate Strategy and Health Policy. In this role, he established Novocure’s health policy and business development groups, and additionally led various finance functions.
Prior to joining Novocure, Mr. Leonard was a venture capital investor focused on high-impact medical technologies. Mr. Leonard holds an A.B. from Harvard and an M.A. from the London School of Economics and Political Science.
Mr. Leonard joined Novocure in 2010 to help prepare the company for the commercial launch of Optune®. He most recently served as Chief Development Officer. In this role, he was responsible for engineering, product development, business development and the overall strategic and operational leadership of Novocure’s innovation platforms. He previously served as the Senior Vice President for Corporate Strategy and Health Policy. In this role, he established Novocure’s health policy and business development groups, and additionally led various finance functions.
Prior to joining Novocure, Mr. Leonard was a venture capital investor focused on high-impact medical technologies. Mr. Leonard holds an A.B. from Harvard and an M.A. from the London School of Economics and Political Science.